139 related articles for article (PubMed ID: 1736805)
1. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
[TBL] [Abstract][Full Text] [Related]
2. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
3. A prospective evaluation of CA15-3 in stage I carcinoma of the breast.
O'Hanlon DM; Kerin MJ; Kent PJ; Skehill R; Maher D; Grimes H; Given HF
J Am Coll Surg; 1995 Feb; 180(2):210-2. PubMed ID: 7850057
[TBL] [Abstract][Full Text] [Related]
4. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
[TBL] [Abstract][Full Text] [Related]
5. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
6. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
7. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
Horobin JM; Browning MC; McFarlane NP; Smith G; Preece PE; Wood RA; Cuschieri A
J R Coll Surg Edinb; 1991 Aug; 36(4):219-21. PubMed ID: 1941734
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
[TBL] [Abstract][Full Text] [Related]
9. [Clinical usefulness of tumor markers in breast cancer].
Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
[TBL] [Abstract][Full Text] [Related]
11. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
Oremek G; Sauer-Eppel H; Klepzig M
Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
[TBL] [Abstract][Full Text] [Related]
12. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
Einarsson R; Lindman H; Bergh J
Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
[TBL] [Abstract][Full Text] [Related]
13. [Immunoradiometric assay of tumor marker CA15-3 and its clinical application].
Chen Z; Fan Z; Yang J
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):125-8. PubMed ID: 10920962
[TBL] [Abstract][Full Text] [Related]
14. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
[TBL] [Abstract][Full Text] [Related]
15. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
16. [Considerations in rational use of tumor markers in breast carcinoma].
Crombach G
Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
[TBL] [Abstract][Full Text] [Related]
17. [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients].
Loibl S; Königs A; Kaufmann M; Costa SD; Bischoff J
Zentralbl Gynakol; 2006 Dec; 128(6):330-5. PubMed ID: 17213971
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
Tondini C; Hayes DF; Gelman R; Henderson IC; Kufe DW
Cancer Res; 1988 Jul; 48(14):4107-12. PubMed ID: 3164256
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer.
Martín A; Corte MD; Alvarez AM; Rodriguez JC; Andicoechea A; Bongera M; Junquera S; Pidal D; Allende T; Muñiz JL; Vizoso F
Anticancer Res; 2006; 26(5B):3965-71. PubMed ID: 17094428
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
